We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Deltex Medical Group Plc | LSE:DEMG | London | Ordinary Share | GB0059337583 | ORD 0.01P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.005 | 3.85% | 0.135 | 0.13 | 0.14 | 0.135 | 0.13 | 0.13 | 130,555 | 09:18:03 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electromedical Apparatus | 2.48M | -1.15M | -0.0006 | -2.17 | 2.4M |
Date | Subject | Author | Discuss |
---|---|---|---|
25/1/2018 08:47 | I went for a few in the placing although I still don't have exact details of my allocation for some reason. Apparently I have been scaled back by around 20% but TPI cannot give me an exact number for some reason. It looks like the placing shares may qualify for EIS/VCT tax breaks, so the effective purchase price for placees could be just 0.875p/share "The Directors believe that HMRC would be able to authorise the Company to issue compliance certificates under section 204(1) of the Income Tax Act 2007 in respect of New Ordinary Shares issued to individuals, following receipt from the Company of a properly completed compliance statement (Form EIS1) within the prescribed time limit stipulated in section 205(4) of the Income Tax Act 2007. The continuing status of the New Ordinary Shares as qualifying for EIS purposes will be conditional upon the qualifying conditions being and remaining satisfied throughout the relevant period of ownership. There can be no guarantee that any investment in the Company will remain a qualifying investment for EIS purposes. EIS eligibility is also dependent on a shareholder's own position and not just that of the Company. Accordingly, investors should take their own tax advice in this regard from a duly-qualified professional adviser. None of the Company, Arden, TPI or the Registrars is able to give any Shareholder or any other person any advice in relation to their tax position." I shall go along to the EGM on Feb 9th (assuming its London based) and encourage the CFO to chase HMRC regarding the EIS/VCT approval process. | timbo003 | |
24/1/2018 18:44 | ===> Gnmartin 9213 The effect on costs for the NHS depend on which is the relevant limiting factor: * Surgeon time, *Specialist or other nursing staff *Bed numbers Since ODM only impacts on LOS rather than operating time, the question is how the NHS responds to freed capacity of the limiting factor beds. Assuming that nursing staff is directly proportional to the number of beds occupied, again the requirement for nursing would remain the same if the number of operations undertaken increased by a factor of the LOS saving to fill freed bed capacity. However, we know that the NHS response to empty beds is not to increase operations it is to either to eliminate the beds or use them for other purposes. Even in the unlikely event that the NHS decided to increase the number of operations ( where would the specialist staff required come from?)as you say, this would only continue until the backlog had been eliminated after which time the overall cost would fall on account or reduced LOS and remain lower ongoing. In view of the fact that bed-blocking is ensuring that beds are generally fully occupied, the most likely effect is that there will be a diminution in the number of patients requiring Care being prematurely released without somewhere to go because of lack of capacity in Social Care. So the idea that NHS costs will increase would only apply in the short run but even then it is unlikely. | doglover2003 | |
24/1/2018 12:04 | Part of the problem for the NHS is that ODM may actually increase their costs. If the NHS manages more operations per week, then their costs will rise: more surgeon hours, more material costs, etc. ODM only helps reduce NHS spend if the reduction in hospital bed time per patient means a reduced need for hospital beds rather than an increased ability to meet demand. In the USA the demand is choked off by cost rather than by hospital spaces, and the hospitals are given an incentive to reduce the total cost per patient by being made responsible (I believe, at least under Obamacare) for the cost of any complication or recall. | gnnmartin | |
23/1/2018 11:22 | ...and the further irony is that the finance director probably invented the system, supposedly to save money, which actually increases costs. | arf dysg | |
23/1/2018 11:17 | I thought we'd heard before about silo budgeting. The surgery budget won't pay for ODM because it benefits someone ELSE'S budget. The irony is that the same budget manager probably goes home and decides to spend money on double glazing, cavity-wall insulation and loft insulation because it will reduce his heating costs. | arf dysg | |
23/1/2018 10:59 | I guess will find out in the next year from the US sales, whether the lack of UK sales is genuinely due to budget constraints or whether ODM is simply not important enough in the UK. It could just be that in the UK, because of the way its run, any financial or other benefits of reduced stay do not end up being quantified in a way that justifies the spend. That sounds ridiculous, but it wouldn't surprise me. I wonder what other beneficial practices go by the wayside because the budget is spent in one department and the benefits felt in another. As for the news about not having enough beds for this winter, isn't it time that all the decision makers who closed entire wards back in the Blair days, were hauled in front of a select committee and asked wtf they thought they were doing and forced to give up any private health care they have and told they will have to use the NHS from now on. What they reaped they should sow. | yump | |
23/1/2018 10:52 | Still a chance. | gnnmartin | |
23/1/2018 10:43 | I make that another 168 million new shares. Existing number of shares, according to the announcement on 25th of September 2017: 313,213,367 This doesn't include any options which haven't been taken up yet. Ergo, this increases the number of shares by slightly over 50%, which means that, after the placing, today's shares will have only two thirds of their previous value. | arf dysg | |
23/1/2018 09:16 | 2013 UK sales = £4.3m 2017 UK sales = £1.5m | maxk | |
23/1/2018 08:47 | As predicted here is the placing.Totally stitched up.Unbelievable. | trentendboy | |
23/1/2018 08:34 | Massive dilution but enough cash to last 3 or 4 years and if the business hasnt taken off by then it never will. | amt | |
23/1/2018 08:00 | Makes me wonder if the price spike to 2p and the timing of the new hospital win was connected somehow to this placing... or maybe I’ve been in this game way too long. No longer a holder, as even with the shelf life of jam, tomorrow never came and it finally went off - and I lost my patience (after 10 years!) | cisk | |
23/1/2018 07:39 | Looks like they've gone for one big placing, rather than messing with a few hundred K. Big dilution. | yump | |
23/1/2018 07:34 | Is DEMG good value @ 1.55p? With offer of 1.25p looming your probably better buying as many as you like in the open market, I'm expecting the share price to drop below offer price initially!! | gbenson1 | |
23/1/2018 07:21 | Well here it is finally, the inevitable placing. I won't be subscribing to a single additional share as this is a croc of merd! I can't recall what price I bought these at but think it was 15p or thereabouts | audigger | |
22/1/2018 22:46 | Er, try the ADVFN news tab on DEMGBut they didn't say which one they were better than this timeWho do think it was? Or was it more than one?Exciting, isn't it? We might one day find out what we already knowMrShyLock2U | mrc2u | |
22/1/2018 18:24 | Can anyone supply a link to the results data re the latest RNS What other monitors were tested V DEMG ODM ? | buywell3 | |
22/1/2018 11:02 | Come on then, who is going to average down at 1.5p ? All or nothing in the next 2 years... | yump | |
22/1/2018 10:11 | mrC2u (9195) "Buywell [...] So where are you getting your running total from?" He pulled it out of his.. He pulled it out of his a.. He pulled it out of his as.. He pulled it out of his astute appraisal of the situation. | arf dysg | |
19/1/2018 18:45 | Buywell"In the future, we do not intend to announce new large account wins unless they are of particular note" 11 September 2017So where are you getting your running total from? Is it the same place as your insight into margin slashing?MrShyLock2U | mrc2u | |
19/1/2018 17:25 | DEMG have 33 USA accounts , the numbers added in the last year have been dropping This latest account is number 34 I believe Monies raised from the USA accounts has not helped turn things around though and I don't see account number 34 changing things within the next 6 weeks that DEMG has to raise money to keep on trading when the £189k it has left runs out. Existing Loan notes have to be repaid in 2019 Debt is a problem as it the lack of cash With the share price falling back , 1p looks like being the price that might attract money from somewhere IF the company acts quick. | buywell3 | |
19/1/2018 10:31 | Confused. You will be if you even bother to read the posts from the person with a name that is in complete contradiction to the evidence of their brain capacity from the posts. Evaluation to implementation of 13 months seems quite short by clinical standards. I thought the idea was to run an evaluation that proves the case, then debate amongst as many peers as you can for a year or so, run a few conferences etc. etc., say you're going to move it at pace an scale and then wait for someone to do something. Oh sorry, I was thinking about the UK. | yump | |
19/1/2018 10:30 | Good one, Buywell. Indeed mastertrolling to suggest, presumably without any evidence, that they must have slashed margin to the bone to get this deal away in US. Thought they had 90% or more margin in US so how much flesh, precisely, are you suggesting they carved away?MrC (aka Shylock) | mrc2u |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions